UGTs are of particular physiological, pharmacological, and toxicological significance due to their involvement in biotransformation of the largest number of endogenous compounds, drugs, and environmental toxins of different chemical structures and origins of any phase II metabolizing enzyme. Moreover, some UGT substrates, which are nuclear receptor ligands, signaling molecules, important drugs, and environmental chemicals, can affect UGT mRNA expression and alter the activity of the UGT enzymes. There is a tremendous need for the understanding of the pharmacogenetics and drug interactions of chemicals that are substrates for and inducers of UGTs. Due to the lack of homogeneous proteins for structural studies, it was previously impossible to predict the molecular mechanism of glucuronidation required to understand the mechanistic aspects of UGT substrate specificity, inhibition, and drug-drug interactions. Now that homogeneous UGT proteins have been generated, studies identifying UGT active sites are proposed. Our central hypothesis is that the N-terminal domain of UGTs consists of distinct substrate recognition sequences (SRSs) that display specificity for classes of UGT substrates and, thus, determine the catalytic mechanism and substrate specificity of individual UGT isoforms. For the co- substrate active site, we hypothesize that the site of UDP/Mg2+ binding is localized in the highly conserved C-terminal end of the UGT molecule. Specifically, we postulate that a DxxD motif, conserved in all UGTs. is a major element of the UDP-GlcUA (co-substrate) binding site. These hypotheses will be tested by the following Specific Aims: 1. To identify and characterize the substrate recognition sequences of UGTs. 2. To identify and characterize the UDP-GlcUA binding site of UGTs. 3. To sequence photolabeled polypeptides by mass spectrometry. 4. To modify amino acid motifs of putative binding sites by site-directed mutagenesis and catalytically characterize the generated mutants. The information derived from the proposed studies will provide insight into the molecular mechanism of glucuronidation and will enhance our ability to predict and direct the metabolic transformation of both endogenous and exogenous substrates for UGTs. This information will be important for understanding specific interactions between endogenous substrates and drugs. It will also serve as a basis in the search for new drugs and inhibitors of specific UGT isoforms, thus affecting drug therapy, drug-drug interactions, and the risk of chemically-induced diseases, including cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM075893-08
Application #
7666021
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
1996-06-01
Project End
2012-07-31
Budget Start
2009-08-01
Budget End
2012-07-31
Support Year
8
Fiscal Year
2009
Total Cost
$261,921
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Biochemistry
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Greer, Aleksandra K; Madadi, Nikhil R; Bratton, Stacie M et al. (2014) Novel resveratrol-based substrates for human hepatic, renal, and intestinal UDP-glucuronosyltransferases. Chem Res Toxicol 27:536-45
Prather, Paul L; FrancisDevaraj, FeAna; Dates, Centdrika R et al. (2013) CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Commun 441:339-43
Pawlowska, Monika; Chu, Rong; Fedejko-Kap, Barbara et al. (2013) Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use. Drug Metab Dispos 41:414-21
Chimalakonda, Krishna C; James, Laura P; Radominska-Pandya, Anna et al. (2013) Sulfaphenazole and ?-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab Lett 7:34-8
Chimalakonda, Krishna C; Seely, Kathryn A; Bratton, Stacie M et al. (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174-84
Seely, Kathryn A; Brents, Lisa K; Radominska-Pandya, Anna et al. (2012) A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors. Chem Res Toxicol 25:825-7
Brents, Lisa K; Medina-Bolivar, Fabricio; Seely, Kathryn A et al. (2012) Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors. Xenobiotica 42:139-56
Fedejko-Kap, Barbara; Bratton, Stacie M; Finel, Moshe et al. (2012) Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10. Drug Metab Dispos 40:1736-43
Bratton, Stacie M; Mosher, Carrie M; Khallouki, Farid et al. (2012) Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 340:46-55
Chimalakonda, Krishna C; Bratton, Stacie M; Le, Vi-Huyen et al. (2011) Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos 39:1967-76

Showing the most recent 10 out of 28 publications